Special Issue

Biomarkers for Neurodegenerative Disorders

Message from the Guest Editor

Neurodegenerative disorders are characterized by progressive neuronal loss in the central nervous system, which leads to various symptoms and/or neurological findings according to a damaged cell type and lesions. In principle, these disorders are diagnosed by pathological findings including aggregates of proteins, part of which are now visualized by amyloid beta and tau positron emission tomography (PET) in several hospitals and institutions. However, PET is not easy to access due to high invasiveness, high cost, the short half-life of the tracer, and limited availability. We need readily available biomarkers, such as magnetic resonance imaging (MRI), MR spectroscopy (MRS), electroencephalography (EEG), polysomnography (PSG), and proteins in cerebrospinal fluid (CSF) or blood, to fill the gap between pathology and clinical practice. This Special Issue aims to bring together a collection of cutting-edge research that focuses on diagnostic biomarkers as well as prognostic biomarkers for neurodegenerative disorders. I welcome studies with a small sample size if the highlighted method is novel and attractive. I hope this Special Issue will be of great help to clinical practice.

Guest Editor

Dr. Wataru Sako

Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan

Deadline for manuscript submissions

closed (31 July 2021)



Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



mdpi.com/si/65786

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

mdpi.com/journal/diagnostics





Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

